Molecular Cloning, Chromosomal Mapping, and Characterization of the Human Cardiac-Specific Homeobox Gene *hCsx*

David Turbay, 1 Stephanie Burns Wechsler, 1 Kristina McQuate Blanchard, and Seigo Izumo 1 turbay 1 tur

Cardiovascular Research Center and Departments of Internal Medicine, [†]Pediatrics and Communicable Diseases, and [‡]Biological Chemistry, University of Michigan Medical Center, Ann Arbor, Michigan, U.S.A.

ABSTRACT

Background: *Csx/Nkx2.5,* a murine nonclustered homeobox gene expressed primarily in the heart, has significant sequence similarity to the *Drosophila tinman* gene. *Tinman* is essential for heart and gut formation in *Drosophila.* Targeted mutation in the mouse gene, *Csx/Nkx2.5,* arrests cardiac development during early embryonic stages, suggesting an evolutionary conservation in cardiogenesis.

Materials and Methods: We have isolated and characterized a human homolog, *hCsx*, from an adult cardiac cDNA library. Northern blotting and ribonuclease protection was used to define the pattern of expression during normal development and in disease states. Chromosomal localization of the gene was determined by somatic cell hybrid analysis and fluorescent in situ hybridization.

Results: The predicted amino acid sequence of *hCsx* has 87% overall homology to the murine gene with 100% identity in the homeodomain. The homeodomain sequence of *hCsx* is 95% identical to its *Xenopus* homolog,

and 65% to *tinman*. *hCsx* mRNA was detected exclusively in the heart. *hCsx* transcript was detected at 12 weeks in human embryonic heart, the earliest time point examined, and was up-regulated 5-fold between 12 and 19 weeks. There was no significant alteration of *hCsx* message level in the myocardium of 14 patients with end stage heart failure compared to a normal control. The human gene mapped to the distal portion of chromosome 5, the 5q34–q35 region. This defines a new synteny region between human chromosome 5q and the *t*-locus of mouse chromosome 17, where the mouse *Csx* gene is located.

Conclusions: *hCsx*, the human homolog of *Drosophila tinman*, is expressed in heart in a tissue restricted manner. Distal 5q trisomies produce several phenotypic abnormalities, including a high incidence of congenital heart disease. Isolation of the *hCsx* gene will allow further studies of mutations in this gene and their potential associations with some forms of congenital heart disease in humans.

INTRODUCTION

The coordinated activation of regulatory genes plays a determinant role in the developmental process. The identity of any given cell lineage is

Address correspondence and reprint requests to: Seigo Izumo 7220 MSRB III, The University of Michigan Medical Center, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0644, U.S.A.

¹Present address: Division of Immunogenetics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, U.S.A. finally determined by the complement of genes activated in the correct spatiotemporal fashion. Genes encoding transcription factors are particularly important because they control the expression of downstream target genes in this process. Activation of transcription factors can initiate a genetic cascade determining the final developmental destinies of groups of cells that will become a specific organ or tissue. The discovery of the MyoD family of transcription factors was a major breakthrough for the under-

standing of the genetic cascade leading to skeletal muscle development (1). These myogenic regulatory factors (MyoD, myogenin, *myf*-5 and MRF4) share a basic helix-loop-helix motif that binds to a *cis*-regulatory element called the E-box in the enhancers of different muscle specific genes (2). Skeletal and cardiac myocytes share several contractile proteins. Nevertheless, mice homozygous for null mutations in MyoD and *myf*-5 genes show a complete absence of skeletal muscle but no gross abnormality of the heart pointing to a divergent regulation between these two striated muscle cell types (3).

Homeobox genes are master regulatory genes that specify the body plan of metazoans (4). They share a common motif of 180 bp, the homeobox, which encodes the 60 amino acid homeodomain, the DNA-binding domain of this family of proteins (5). Some homeobox genes are organized in complexes (clustered), while others are randomly dispersed (nonclustered) throughout the genome (6). The clustered superfamily of homeobox genes seems to arise from a single cluster in the primitive metazoans (7). It is likely that as different organisms became genetically and anatomically more complex, duplications of the primordial genes arose. There are two clusters (Antennapedia and Bithorax) in Drosophila and four clusters (HoxA to HoxD) in mouse and human. These genes are organized in the same order along the chromosome as they are expressed along the antero-posterior body axis in what is known as the colinearity rule (8). Over- and mis-expression of some members of the Hox gene family, as well as null mutation analyses suggest that vertebrate Hox-type homeobox genes function in a similar way as their invertebrate homologs (8). In the nonclustered homeobox superfamily there are several mammalian homologs of each Drosophila gene which are named after the insect gene. They include the POU-family, paired-family, LIM-family, and NK-family, among others (6). These randomly inserted genes do not follow the colinearity rule, often contain additional conserved motifs, and may play a critical role in tissue specification during development (8).

A homeobox gene whose expression pattern is restricted to specific cell lineages during development would be of significant interest as a candidate tissue-specification gene. There has been a recent interest in the *Drosophila* NK homeobox gene family (9), as a group of genes which may specify cell fates of various tissues due to the

restricted tissue expression of many of these genes. For example, the NK-1/S59 gene is expressed in the somatic mesoderm, in anterior portions of the central nervous system, and in the midgut of Drosophila (10). Rodent NK-2 homologs are expressed in a tissue restricted fashion: mNKx2.1/TTF-1 is expressed in the thyroid anlage, the lung bud, and the developing brain; mNKx2.2 and mNKx2.4 are expressed in certain areas of the central nervous system; and mNKx2.3 is expressed in the developing gut (11,12). Expression of the NK-3/bagpipe gene is restricted to the gut and a subset of heart progenitors in Drosophila (10). In the bagpipe mutant embryos, visceral mesoderm formation is disrupted, suggesting the requirement of bagpipe for gut development (13).

The NK-4/tinman gene is expressed in the heart precursor cells of the dorsal mesoderm (14). Tinman mutants do not form the dorsal vessel, the *Drosophila* equivalent of the vertebrate heart (13,15). Tinman has several different vertebrate relatives (16). The mouse gene, Csx/ Nkx2.5 is expressed from Day 7.5 postcoitum (p.c.) in the cardiac progenitor cells and its cardiac expression continues through the adult stage (17,18). Targeted disruption of Csx/Nkx2.5 results in abnormal heart morphogenesis and embryonic lethality around 9-10 days p.c. (19). In null mutant embryos, the beating linear heart tube forms normally but cardiac myogenesis is arrested at 8.5 days p.c. when the looping process occurs, with subsequent death within 1-2 days (19).

It is important to point out that in addition to the homeobox genes, there are two other transcription factors, *GATA-4* and *MEF2C*, expressed in the murine precardiac mesoderm that are also candidate regulatory genes for cardiac morphogenesis (20,21). To date, the exact roles of these transcription factors in mammalian cardiac development have not been elucidated.

Due to the significant functional conservation of the *Csx*-like genes among species, it may be hypothesized that a human homolog of *tinman* exists and may be related to some forms of congenital heart disease and other cardiac pathologic states. In the present study, we report the cloning of the human homolog of the *Csx/Nkx2.5* gene, *hCsx*. Its sequence, chromosomal location, expression pattern in normal tissues and disease states are presented.

MATERIALS AND METHODS

Cardiac cDNA Library Screening and DNA Sequencing

A lambda gt10 library (a gift from Dr. Seth Alper) prepared from a single adult human left ventricle (22) was screened with a PstI fragment of mouse Csx containing the conserved homeobox and NK2 box (17). Low stringency hybridizations were performed with 35% formamide, 1% SDS, 2×SSC, 10% Dextran sulfate and salmon sperm DNA at 42°C. DNA sequencing reactions were carried out using the Taq DyeDeoxy Terminator or DyePrimer cycle sequencing kit (Applied Biosystems, Foster City, CA, U.S.A.). Both strands were sequenced on an automated DNA Sequenator (Applied Biosystems 370A) by the DNA Sequencing Core Facility (Ann Arbor, MI, U.S.A.). Sequence analysis was performed with MacVector and AssemblyLIGN software (Eastman Kodak, Rochester, NY, U.S.A.). Database searches were performed using the BLAST program (Whitehead Institute for Biomedical Research, Cambridge, MA, U.S.A.).

Ribonuclease Protection Analysis

We analyzed left ventricle RNA previously isolated from adult patients with end-stage heart failure of different etiologies, undergoing cardiac transplant surgery at Brigham and Women's Hospital (Boston, MA, U.S.A.) (23). The subjects included six patients with idiopathic dilated cardiomyopathy, six with ischemic cardiomyopathy, and two adults with congenital heart disease (one with L-transposition of great vessels and one with an atrial septal defect and congenital mitral stenosis, both of whom had undergone prior cardiac surgery). RNA samples of organ donors with no known cardiac pathology were used as controls. To examine developmental changes, the previously described ventricular RNA samples (23) from artificially aborted fetuses (gestation 12-19 weeks) were used. The original protocol of human cardiac tissue procurement (Dr. Paul D. Allen, Brigham and Women's Hospital) was approved by the institutional review board as previously described (23).

Ribonuclease (RNase) protection assays were performed essentially as described (24). The 32 P-labeled hCsx probe was synthesized by runoff transcription with T3 RNA polymerase from the pBluescript plasmid (Stratagene, La Jolla, CA, U.S.A.) containing the full length hCsx cDNA linearized with AvaII. The γ -actin probe was simi-

larly synthesized with SP6 RNA polymerase from a HinfI-linearized plasmid, pSP64 (a gift from Dr. Ellis J. Neufeld) containing a portion of the 3'-untranslated region of the human γ -actin gene. Five micrograms of total human ventricular RNA was used for each protection with 10 μ g of yeast tRNA as a negative control in each experiment. All samples were simultaneously hybridized with hCsx and γ -actin probes. All hybrids were digested with RNase A and RNase T1 at 37°C for 30 min. The digested products were run on 6% denaturing gels, followed by autoradiography. Relative amounts of mRNA were determined by densitometry in the linear response range of the X-ray films for each message.

Southern and Northern Blot Analysis

Human genomic DNA was extracted from mononuclear blood cells as described previously (24), and used for Southern blotting. Ten micrograms genomic DNA samples were digested with *BamH1*, *EcoR1*, or *HindIII* then electrophoresed in a 0.8% agarose gel and transferred to a Hybond-N Nylon membrane (Amersham Life Science, Arlington, IL, U.S.A.). The membranes were hybridized as previously described (25) and washed under high stringency to a final wash in 0.1×SSC, 0.5% SDS at 65°C. After this, the blots were subjected to autoradiography.

A human multiple tissue Northern blot containing approximately 2 μ g of poly A⁺ RNA per lane from different human tissues was obtained (Clontech, Palo Alto, CA, U.S.A.). The blot was hybridized and washed following the manufacturer's directions.

Chromosomal Location and Intron-Exon Mapping

Chromosomal mapping was first determined by somatic cell hybrid analysis. The Human/Rodent Somatic Cell Hybrid Panel #2 was obtained from NIGMS (Coriell Institute for Medical Research, Camden, NJ, U.S.A.). The presence of the *hCsx* gene was determined by polymerase chain reaction (PCR) performed with 200 ng hybrid genomic DNA, 500 μ M each primer, 10 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM MgCl₂, 0.01% gelatin, 200 μ M dNTPs, and 1.5 units of AmpliTaq DNA polymerase (Perkin Elmer-Cetus, Norwalk, CT, U.S.A.) in a final volume of 25 μ l. The primers used were, sense (from the 3' coding region, P1S): 5'-AACTTCGTGAACTTCGGCGTC-3', and antisense (from the 3' untranslated re-

gion, P1AS): 5'-GTCTCCGCAGGAGTGAATG-3' (see Figure 2B below). After an initial denaturation step for 5 min at 95°C, the samples were amplified for 30 additional cycles at 94°C for 1 min, 60°C for 30 sec and 72°C for 30 sec. The 229-bp human specific product was visualized on a 2% agarose gel stained with ethidium bromide, subcloned into the pCR II vector (Invitrogen, San Diego, CA, U.S.A.) and sequenced.

A human genomic P1 clone containing the hCsx gene was obtained by screening a human foreskin fibroblast P1 library by PCR (26,27) with the primers described above. The primers used to amplify the intronic sequence of the hCsx P1 clone were, sense (from the 5' coding region, P4S): 5'-TGTGCGTCTGCCTTTCC-3' and antisense (from homeodomain, P4AS): 5'-TGCGTG GACGTGAGTTTCAG-3' (see Fig. 2B below) following the same PCR conditions described above. The P1 plasmid containing the hCsx genomic clone was used as a probe and fluorescence in situ hybridization (FISH) was performed as described previously (28) by the Cancer Center Cytogenetic Core Facility (Ann Arbor, MI, U.S.A.).

RESULTS

Cloning of the Human Cardiac-Specific Homeobox (hCsx) cDNA

Screening of a human ventricular cDNA library using the murine Csx cDNA probe resulted in the isolation of five positive clones from approximately 2×10^6 recombinants. Partial sequencing and restriction mapping indicated that these clones represented a single transcript, hCsx. Sequence analysis (Fig. 1) revealed a single open reading frame with a putative initiation codon preceded by a strong Kozak consensus initiation sequence (29). The longest hCsx cDNA clone is 1585 nucleotides in length that predicts a protein of 323 amino acids with no poly(A) tail at the 3' end. Overall, the predicted hCsx protein sequence has 87% identity with its mouse homolog and about 60% with the Xenopus homolog, XCsx2/ XNkx2.5 (Ref. 30 and Issei Komuro, Yu Chang Fu, D.T., and S.I., unpublished data). The homeodomain sequence of hCsx is 100% identical to its mouse homolog and 95% to its Xenopus homolog (Fig. 2A, a). There are two other conserved domains in the hCsx sequence, the TN-domain and the NK2 box, located amino- and carboxy-terminal to the homeobox, respectively. Interestingly, in the regions corresponding to the conserved

51	GAC	ACATO	CAG	GCC	TGG	CCCC	CCTC	TCC	rgcco	CTTC	TGC	CAGO	GCTA	ACCTO	SCTG	CCCG
114	AGG	GCCC	TGG	GCAG	CGCC	CTT:	CTC	CCCC	CCAC	TGG	CCTC	STGAC	CACT	GCGC	CTGC	CACC
177	ATG	TTC	CCC	AGC	CCT	GCT	CTC	ACG	CCC	ACG	CCC	TTC	TCA		AAA	
1	Met	Phe	Pro	Ser	Pro	Ala	Leu	Thr	Pro	Thr	Pro	Phe	Ser	Val	Lvs	Asp
											• • •	• • •				• • •
225	ATC	CTA	***	CTG	C 3 3	CNC	CNC	CNC	ccc	300	~~~	CCT	ccc	ccc	CC3	CAC
17		Leu	Aen	Leu	GAA	Gln	Gln	Gln	Ara	Sor	Len	Δla	Δla	Δla	Gly	Glu
1,		шеш	0011	Deu	Giu	GIII	GIII	GIII	nrg	Der	Dea		niu	Ses	GLY	Aen
		• • •									•••		• • •	503		nop
273	CTC	TCT	GCC	CGC	CTG	GAG	GCG	ACC	CTG	GCG	CCC	TCC	TCC	TGC	ATG	CTG
33	Leu	Ser	Ala	Arg	Leu	Glu	Ala	Thr	Leu	Ala	Pro	Ser	Ser	Cys	Met	Leu
												Ala				
321 49	GCC	GCC	TIC	AAG	CCA	GAG	GCC	TAC	GCT	GGG	CCC	GAG	GCG	GCT	GCG	CCG
49	Ala	Ala	Pne	Lys	Pro	GIU	AIA	lyr	Ser	GIÀ	PIO	GIU	Ala	Ald	AId	Ser
				• • •	• • • •	• • • •	• • •		Ser		• • •				• • •	Jer
369	GGC	CTC	CCA	GAG	CTG	CGC	GCA	GAG	CTG	GGC	CGC	GCG	CCT	TCA	CCG	GCC
65	Glv	Leu	Pro	Glu	Leu	Arq	Ala	Glu	Leu	Gly	Arg	Ala	Pro	Ser	Pro	Ala
			Ala						Met		Pro					Pro
417	AAG	TGT	GCG	TCT	GCC	TTT	ccc		GCC		GCC	TTC	TAT	CCA	CGT	GCC
81	Lys	Cys	Ser	Pro	AIA	Pne	Pro	Ala	Ala	Pro	Thr	rne	ıyr	Pro	Arg Gly	Ala
	• • •		ser	Pro	• • •	• • •		• • • •	• • • •	• • •	m	• • •	• • •	• • •	GIA	
465	TAC	AGC	GAC	ccc	GAC	CCA	GCC	AAC	GAC	ССТ	ACA	GCC	GAA	AAC	дда	GAG
97	Tyr	Ser	Asp	Pro	Acn	Pro	Δla	Live	Acn	Pro	Ara	Ala	Glu	Lvs	Lys	Glu
		Glv						-,,					Asp	-,-	-,-	
	•••												-			
513	CTG	TGC Cys	GCG	CTG	CAG	AAG	GCG	GTG	GAG	CTG	GAG	AAG	ACA	GAG	GCG	GAC
113	Leu	Cys	Ala	Leu	Gln	Lys	Ala	Val	Glu	Leu	Glu	Lys	Thr	Glu	Ala	Asp
											Asp		Ala		Thr	
561 129	AAC	GCG Ala	GAG	CGG	CCC	CGG	GCG	CGA	CGG	CGG	AGG	AAG	CCG	CGC	GTG Val	CTC Leu
129	Gly	Ala	GIU	Arg	PIO	Arg	Ala	Arg	Arg	Arg	Arg	Lys	PIO	Arg	vai	Leu
							· · ·	• • • •	• • • •							
609	TTC	TCG Ser	CAG	GCG	CAG	GTC	TAT	GAG	CTG	GAG	CGG	CGC	TTC	AAG	CAG	CAG
145	Phe	Ser	Gln	Ala	Gln	Val	Tyr	Glu	Leu	Glu	Arg	Arg	Phe	Lys	Gln	Gln
657		TAC		TCG	GCC	CCC	GAA	CGC	GAC	CAG	CTG	GCC				
161	Arg	Tyr	Leu	Ser	Ala	Pro	GIU	Arg	ASD	Gin	Leu	Ala	Ser	Val	Leu	Lys
		• • •							• • •		• • •	• • •				• • • •
705	CTC	ACG	TCC	ACG	CAG	GTC	AAG	ATC	TGG	TTC	CAG	AAC	CGG	CGC	TAC	AAG
177	Leu	ACG Thr	Ser	Thr	Gln	Val	Lvs	Ile	Trp	Phe	Gln	Asn	Arg	Arg	Tyr	Lys
	1					_										
753 193	TGC	AAG	CGG	CAG	CGG	CAG	GAC	CAG	ACT	CTG	GAG	CTG	GTG	GGG	CTG	ccc
193	cys	Lys	Arg	Gin	Arg	Gin	Asp	GIn	Thr	Leu	GIu	Leu	Leu	GIY	Leu	Pro
	٠::				• • •		• • • •		• • •	• • •	• • •		reu			
801				CCG	CCG	ССТ	GCC	CCC	AGG	ATC	GCG	GTG	CCA	GTG	CTG	GTG
	CCG	CCG	CCG				•1-	Ara	Ara	Tle	Ala	Val	Pro	Val		
209	CCG	CCG	CCG	Pro	Pro	Pro									Len	
209	Pro	CCG	CCG Pro	Pro	Pro	Pro	Ald	DAY.	- ALG					Val	Leu	Val
	Pro	Pro	Pro	Pro	Pro	• • •	• • •	• • •	• • •	• • •	• • •	• • •	• • •	• • •	• • •	•••
849	Pro 	Pro GAT	Pro GGC	Pro AAG	Pro 	TGC	CTA	GGG	GAC	TCG	GCG	ccc	TAC	GCG	 CCT	GCC
849	Pro 	Pro	Pro GGC	Pro AAG	Pro 	TGC	CTA	GGG	GAC	TCG Ser	 GCG Ala	CCC Pro	TAC	GCG	 CCT	GCC
849	Pro 	Pro GAT	Pro GGC	Pro AAG	Pro 	TGC	CTA	GGG	GAC	TCG	 GCG Ala	CCC Pro	TAC	GCG	 CCT	GCC
849 225	CGC Arg	GAT ASD	Pro GGC Gly	Pro AAG Lys	Pro CCA Pro	TGC Cvs	CTA Leu	GGG Glv	GAC Asp	TCG Ser Pro	GCG Ala	CCC Pro Ala	TAC Tyr	GCG Ala	CCT Pro	GCC Ala
849 225 897	CGC Arg 	GAT ASD 	GGC Gly GTG	Pro AAG Lvs GGC	Pro CCA Pro 	TGC CVS	CTA Leu 	GGG Glv 	GAC ASD GGT	TCG Ser Pro	GCG Ala	CCC Pro Ala	TAC Tyr 	GCG Ala 	CCT Pro 	GCC Ala
849 225	CGC Arg	GAT ASD 	Pro GGC Gly	Pro AAG Lvs GGC	Pro CCA Pro	TGC CVS	CTA Leu CCC Pro	GGG Glv 	GAC Asp	TCG Ser Pro	GCG Ala	CCC Pro Ala	TAC Tyr 	GCG Ala	CCT Pro 	GCC Ala
849 225 897	CGC Arg 	GAT ASD 	GGC Gly GTG	Pro AAG Lvs GGC	Pro CCA Pro 	TGC CVS	CTA Leu 	GGG Glv 	GAC ASD GGT	TCG Ser Pro	GCG Ala	CCC Pro Ala	TAC Tyr 	GCG Ala 	CCT Pro 	GCC Ala
849 225 897 241	CGC Arg TAC Tyr	GAT ASD GGC Gly	GGC Gly GTG Val	AAG Lys GGC Gly	Pro CCA Pro CTC Leu	TGC CVS AAT ASD	CTA Leu CCC Pro Ala	GGG Glv TAC Tyr	GAC ASD GGT Gly	TCG Ser Pro TAT Tyr	GCG Ala AAC Asn	CCC Pro Ala GCC Ala	TAC Tyr TAC Tyr	GCG Ala CCC Pro	CCT Pro GCC Ala	GCC Ala TAT Tyr
849 225 897 241	CGC Arg TAC Tyr 	GAT ASD GGC Gly GGT	GGC Gly GTG Val 	AAG Lys GGC Gly 	Pro CCA Pro CTC Leu GGC	TGC CVS AAT ASD 	CTA Leu CCC Pro Ala	GGG Glv TAC Tyr	GAC ASD GGT Gly 	TCG Ser Pro TAT Tyr	GCG Ala AAC Asn 	CCC Pro Ala GCC Ala 	TAC Tyr TAC Tyr 	GCG Ala CCC Pro 	CCT Pro GCC Ala 	GCC Ala TAT Tyr
849 225 897 241	CGC Arg TAC Tyr	GAT ASD GGC Gly GGT	GGC Gly GTG Val 	AAG Lys GGC Gly	Pro CCA Pro CTC Leu GGC	TGC CVS AAT ASD 	CTA Leu CCC Pro Ala	GGG Glv TAC Tyr	GAC ASD GGT Gly 	TCG Ser Pro TAT Tyr	GCG Ala AAC Asn 	CCC Pro Ala GCC Ala 	TAC Tyr TAC Tyr 	GCG Ala CCC Pro	CCT Pro GCC Ala	GCC Ala TAT Tyr
849 225 897 241 945 257	CGC Arg TAC Tyr CCG Pro	GAT ASD GGC Gly GGT GGT Gly Ser	GGC Gly GTG Val TAC Tyr	AAG Lys GGC Gly GGC Gly	Pro CCA Pro CTC Leu CTC Leu CTC CHC CTC CTC CTC CTC CTC CTC CTC CTC	TGC CVS AAT ASD GCG Ala	CCC Pro Ala GCC Ala	GGG Glv TAC Tyr TGC Cys	GAC ASD GGT Gly AGC Ser	TCG Ser Pro TAT Tyr CCT Pro	GCG Ala AAC Asn GGC Gly	CCC Pro Ala GCC Ala TAC Tyr	TAC Tyr TAC Tyr AGC Ser	GCG Ala CCC Pro TGC Cys	CCT Pro GCC Ala ACT Thr	GCC Ala TAT Tyr GCC Ala
849 225 897 241 945 257	Pro CGC Arg TAC Tyr CCG Pro CCG GCT	GAT ASD GGC Gly GGT GGT GT GT TAC	GGC Gly GTG Val TAC Tyr CCC	AAG Lys GGC Gly GGC Gly 	Pro CCA Pro CTC Leu CGC Gly GGG GGG	TGC CVS AAT Asn GCG Ala 	CTA Leu CCC Pro Ala GCC Ala 	GGG Glv TAC Tyr TGC Cys 	GAC ASD GGT Gly AGC Ser GCG	TCG Ser Pro TAT Tyr CCT Pro 	GCG Ala AAC Asn GGC Gly 	CCC Pro Ala GCC Ala TAC Tyr GCC	TAC Tyr TAC Tyr AGC Ser 	GCG Ala CCC Pro TGC Cys	CCT Pro GCC Ala ACT Thr	GCC Ala TAT Tyr GCC Ala GCC GCC
849 225 897 241 945 257	CGC Arg TAC Tyr CCG Pro	GAT ASD GGC Gly GGT GGT GT GT TAC	GGC Gly GTG Val TAC Tyr CCC	AAG Lys GGC Gly GGC Gly	Pro CCA Pro CTC Leu CGC Gly GGG Gly	TGC CVS AAT Asn GCG Ala 	CTA Leu CCC Pro Ala GCC Ala 	GGG Glv TAC Tyr TGC Cys CCA Pro	GAC ASD GGT Gly AGC Ser GCG	TCG Ser Pro TAT Tyr CCT Pro 	GCG Ala AAC Asn GGC Gly 	CCC Pro Ala GCC Ala TAC Tyr GCC Ala	TAC Tyr TAC Tyr AGC Ser 	GCG Ala CCC Pro TGC Cys	CCT Pro GCC Ala ACT Thr GCC Ala	GCC Ala TAT Tyr GCC Ala
849 225 897 241 945 257	Pro CGC Arg TAC Tyr CCG Pro CCG GCT	GAT ASD GGC Gly GGT GGT GT GT TAC	GGC Gly GTG Val TAC Tyr CCC	AAG Lys GGC Gly GGC Gly 	Pro CCA Pro CTC Leu CGC Gly GGG GGG	TGC CVS AAT Asn GCG Ala 	CTA Leu CCC Pro Ala GCC Ala 	GGG Glv TAC Tyr TGC Cys 	GAC ASD GGT Gly AGC Ser GCG	TCG Ser Pro TAT Tyr CCT Pro 	GCG Ala AAC Asn GGC Gly 	CCC Pro Ala GCC Ala TAC Tyr GCC Ala	TAC Tyr TAC Tyr AGC Ser 	GCG Ala CCC Pro TGC Cys	CCT Pro GCC Ala ACT Thr	GCC Ala TAT Tyr GCC Ala GCC GCC
849 225 897 241 945 257	CGC Arg TAC Tyr CCG Pro CGCT Ala	GGC Gly GGT Gly Ser TAC Tyr	GGC GIV GTG Val TAC Tyr CCC Pro	AAG Lys GGC Gly GGC Gly GCC Ala	Pro CCA Pro CTC Leu CTC GGC Gly GGG Gly Ala	TGC CVS AAT ASN GCG Ala CCT Pro	CTA Leu CCC Pro Ala GCC Ala TCC Ser Pro	GGG Glv TAC Tyr TGC Cys CCA Pro Ala	GAC ASD GGT Gly AGC Ser GCG Ala	TCG Ser Pro TAT Tyr CCT Pro CAG Gln	GCG Ala AAC Asn GGC Gly CCG Pro	CCC Pro Ala GCC Ala TAC Tyr GCC Ala Pro	TAC Tyr TAC Tyr AGC Ser ACT Thr Ala	GCG Ala CCC Pro TGC Cys GCC Ala	CCT Pro GCC Ala ACT Thr GCC Ala Ser	GCC Ala TAT Tyr GCC Ala GCC Ala
849 225 897 241 945 257 993 273	CGC Arg TAC Tyr CCG Pro GCT Ala	GAT ASD GGC Gly GGT Gly Ser TAC Tyr AAC	Pro GGC Glv GTG Val TAC Tyr CCC Pro	AAG Lys GGC Gly GCC Gly TTC	Pro CCA Pro CTC Leu GGC Gly GGG Gly Ala GTG	TGC CVS AAT ASN GCG Ala CCT Pro AAC	CCC Pro Ala GCC Ala TCC Ser Pro TTC	GGG Glv TAC Tyr Cys CCA Pro Ala GGC	GAC ASD GGT Gly AGC Ser GCG Ala GTC	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG	GCG Ala AAC Asn GGC Gly CCG Pro	CCC Pro Ala GCC Ala TAC Tyr GCC Ala Pro	TAC Tyr TAC Tyr AGC Ser ACT Thr Ala	GCG Ala CCC Pro Cys GCC Ala CCC Ala	CCT Pro GCC Ala ACT Thr GCC Ala Ser	GCC Ala TAT Tyr GCC Ala GCC Ala GCC Ala GCC Ala
849 225 897 241 945 257 993 273	CGC Arg TAC Tyr CCG Pro GCT Ala	Pro GAT Asp GGC Gly GGT TAC TYr AAC Asn	Pro GGC Glv GTG Val TAC Tyr CCC Pro	AAG Lys GGC Gly GCC Gly TTC	Pro CCA Pro CTC Leu GGC Gly GGG Gly Ala GTG	TGC CVS AAT ASN GCG Ala CCT Pro AAC	CCC Pro Ala GCC Ala TCC Ser Pro TTC	GGG Glv TAC Tyr Cys CCA Pro Ala GGC	GAC ASD GGT Gly AGC Ser GCG Ala GTC	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG	GCG Ala AAC Asn GGC Gly CCG Pro	CCC Pro Ala GCC Ala TAC Tyr GCC Ala Pro	TAC Tyr TAC Tyr AGC Ser ACT Thr Ala	GCG Ala CCC Pro Cys GCC Ala CCC GCC	CCT Pro GCC Ala ACT Thr GCC Ala Ser	GCC Ala TAT Tyr GCC Ala GCC Ala
849 225 897 241 945 257 993 273	Pro CGC Arg TAC TYr CCG Pro GCT Ala AAC Asn	Pro GAT ASD GGC Gly GGT TAC TYr AAC Asn Ser	Pro GGC Gly GTG Val TAC Tyr CCC Pro AAC Asn	Pro AAG Lvs GGC Gly GGC Gly GCC Ala TTC Phe	Pro CCA Pro CTC Leu GGC Gly GGly Ala GTG Val	TGC CVS AAT ASn GCG Ala CCT Pro AAC Asn	CTA Leu CCC Pro Ala GCC Ala TCC Ser Pro TTC Phe Pro	GGG Glv TAC Tyr TGC Cys CCA Pro Ala GGC Gly	GAC ASD GGT Gly AGC Ser GCG Ala GTC Val	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly	GCG Ala AAC Asn CCG Gly CCG Pro GAC Asp	CCC Pro Ala GCC Ala La TAC Tyr GCC Ala Pro TTG Leu	TAC Tyr TAC Tyr TAC Tyr AGC Ser Thr Ala AAT Asn	GCG Ala CCC Pro TGC Cys GCC Ala GCG Ala Thr	CCT Pro GCC Ala Thr GCC Ala Ser GTT Val	GCC Ala TAT Tyr GCC Ala GCC Ala GCC Ala GCC Ala
849 225 897 241 945 257 993 273	Pro CGC Arg TAC TYr CCG Pro GCT Ala AAC Asn	Pro GAT ASD GGC Gly GGT TAC TYr AAC Asn Ser	Pro GGC Gly GTG Val TAC Tyr CCC Pro AAC Asn	Pro AAG Lvs GGC Gly GGC Gly GCC Ala TTC Phe	Pro CCA Pro CTC Leu GGC Gly GGly Ala GTG Val	TGC CVS AAT ASn GCG Ala CCT Pro AAC Asn	CTA Leu CCC Pro Ala GCC Ala TCC Ser Pro TTC Phe Pro	GGG Glv TAC Tyr TGC Cys CCA Pro Ala GGC Gly	GAC ASD GGT Gly AGC Ser GCG Ala GTC Val	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly	GCG Ala AAC Asn CCG Gly CCG Pro GAC Asp	CCC Pro Ala GCC Ala La TAC Tyr GCC Ala Pro TTG Leu	TAC Tyr TAC Tyr TAC Tyr AGC Ser Thr Ala AAT Asn	GCG Ala CCC Pro TGC Cys GCC Ala GCG Ala Thr	CCT Pro GCC Ala Thr GCC Ala Ser GTT Val	GCC Ala TAT Tyr GCC Ala CAGGIn GCT
849 225 897 241 945 257 993 273	Pro CGC Arg TAC TYr CCG Pro GCT Ala AAC Asn	Pro GAT ASD GGC Gly GGT TAC TYr AAC Asn Ser	Pro GGC Gly GTG Val TAC Tyr CCC Pro AAC Asn	Pro AAG Lvs GGC Gly GCC Ala TTC Phe ATT Ile	Pro CCA Pro CTC Leu GGC Gly GGly Ala GTG Val	TGC CVS AAT ASn GCG Ala CCT Pro AAC Asn	CTA Leu CCC Pro Ala GCC Ala TCC Ser Pro TTC Phe Pro AGC Ser	GGG Glv TAC Tyr TGC Cys CCA Pro Ala GGC Gly	GAC ASD GGT Gly AGC Ser GCG Ala GTC Val	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly	GCG Ala AAC Asn CCG Gly CCG Pro GAC Asp	CCC Pro Ala GCC Ala La TAC Tyr GCC Ala Pro TTG Leu	TAC Tyr TAC Tyr TAC Tyr AGC Ser Thr Ala AAT Asn	GCG Ala CCC Pro TGC Cys GCC Ala GCG Ala Thr	CCT Pro GCC Ala Thr GCC Ala Ser GTT Val	GCC Ala TAT Tyr GCC Ala GCC Ala CAGGIn
849 225 897 241 945 257 993 273	Pro CGC Arg TAC TYr CCG Pro GCT Ala AAC Asn	Pro GAT ASD GGC Gly GGT Gly Ser TAC Tyr AAC Asn Ser	Pro GGC Gly GTG Val TAC Tyr CCC Pro AAC Asn	Pro AAG Lvs GGC Gly GGC Gly GCC Ala TTC Phe	Pro CCA Pro CTC Leu GGC Gly GGly Ala GTG Val	TGC CVS AAT ASn GCG Ala CCT Pro AAC Asn	CTA Leu CCC Pro Ala GCC Ala TCC Ser Pro TTC Phe Pro	GGG Glv TAC Tyr TGC Cys CCA Pro Ala GGC Gly	GAC ASD GGT Gly AGC Ser GCG Ala GTC Val	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly	GCG Ala AAC Asn CCG Gly CCG Pro GAC Asp	CCC Pro Ala GCC Ala La TAC Tyr GCC Ala Pro TTG Leu	TAC Tyr TAC Tyr TAC Tyr AGC Ser Thr Ala AAT Asn	GCG Ala CCC Pro TGC Cys GCC Ala GCG Ala Thr	CCT Pro GCC Ala Thr GCC Ala Ser GTT Val	GCC Ala TAT Tyr GCC Ala CAGGIn GCT
849 225 897 241 945 257 993 273 1041 289	CGC Arg TAC Tyr CCG Pro GCT Ala AAC Asn AGC Ser	Pro GAT ASD GGC Gly GGT Gly Ser TAC TYr AAC Asn Ser CCC Pro	Pro GGC GIV GTG GTA TAC Tyr CCC Pro AAC Asn GGG GIY	Pro AAG Lys GGC Gly GGC Ala TTC Phe ATT Ile Met	Pro CCA Pro CTC Leu GGC Gly GGG Gly Ala GTG Val CCG Pro	TGC CVS AAT ASN GCG Ala CCT Pro AAC ASN CAG GIN	CCC Pro Ala GCC Ala TCC Ser Pro TTC Phe Pro AGC Ser Gly	GGG GIV TAC TYT TGC Cys CCA Pro Ala GGC GIY AAC AAC	GAC ASD GGT Gly AGC Ser GTC Val TCG Ser	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly	GCG Ala AAC Asn GCG Gly GCG Pro GAC Asp GTG GTG GTG	CCC Pro Ala GCC Ala TAC Tyr GCC Ala Pro TTG Leu TCC Ser	TAC Tyr TAC Tyr AGC Ser Thr Ala AAT Asn ACG Thr	GCG Ala CCC Pro Cys GCC Ala CCG Ala	CCT Pro GCC Ala ACT Thr GCC Ala Ser GTT Val CAT His	GCC Ala TAT Tyr GCC Ala GCC Ala GCC Ala CAG Gln GGT Gly
849 225 897 241 945 257 993 273 1041 289 1089 305	Pro CGC Arg TAC Tyr CCG Pro GCT Ala AAC Asn AGC Ser ATC	Pro GAT ASD GGC Gly GGT Gly Ser TAC Tyr AAC Asn Ser CCC Pro CGA	Pro GGC GIV GTG Val TAC Tyr CCC Pro AAC Asn GGG GIY GCC	Pro AAG Lys GGC Gly GGC Ala TTC Phe ATT Ile Met TGG	Pro CCA Pro CTC Leu GGC Gly GGG Gly Ala GTG Val CCG Pro	TGC CVS AAT ASN GCG Ala CCT Pro AAC ASN CAG GIN	CCC Pro Ala GCC Ala TCC Ser Pro TTC Phe Pro AGC Ser Gly	GGG GIV TAC TYT TGC Cys CCA Pro Ala GGC GIY AAC AAC	GAC ASD GGT Gly AGC Ser GTC Val TCG Ser	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly	GCG Ala AAC Asn GCG Gly GCG Pro GAC Asp GTG GTG GTG	CCC Pro Ala GCC Ala TAC Tyr GCC Ala Pro TTG Leu TCC Ser	TAC Tyr TAC Tyr AGC Ser Thr Ala AAT Asn ACG Thr	GCG Ala CCC Pro Cys GCC Ala CCG Ala	CCT Pro GCC Ala ACT Thr GCC Ala Ser GTT Val CAT His	GCC Ala TAT Tyr GCC Ala CAGGIn GCT
849 225 897 241 945 257 993 273 1041 289	Pro CGC Arg TAC Tyr CCG Pro GCT Ala AAC Asn AGC Ser ATC	Pro GAT ASD GGC Gly GGT Gly Ser TAC TYr AAC Asn Ser CCC Pro	Pro GGC GIV GTG Val TAC Tyr CCC Pro AAC Asn GGG GIY GCC	Pro AAG Lys GGC Gly GGC Ala TTC Phe ATT Ile Met TGG	Pro CCA Pro CTC Leu GGC Gly GGG Gly Ala GTG Val CCG Pro	TGC CVS AAT ASN GCG Ala CCT Pro AAC ASN CAG GIN	CCC Pro Ala GCC Ala TCC Ser Pro TTC Phe Pro AGC Ser Gly	GGG GIV TAC TYT TGC Cys CCA Pro Ala GGC GIY AAC AAC	GAC ASD GGT Gly AGC Ser GTC Val TCG Ser	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly	GCG Ala AAC Asn GCG Gly GCG Pro GAC Asp GTG GTG GTG	CCC Pro Ala GCC Ala TAC Tyr GCC Ala Pro TTG Leu TCC Ser	TAC Tyr TAC Tyr AGC Ser Thr Ala AAT Asn ACG Thr	GCG Ala CCC Pro Cys GCC Ala CCC Ala CC	CCT Pro GCC Ala ACT Thr GCC Ala Ser GTT Val CAT His	GCC Ala TAT Tyr GCC Ala GCC Ala GCC Ala CAG Gln GGT Gly
849 225 897 241 945 257 993 273 1041 289 1089 305	Pro CGC Arg TAC Tyr CCG Pro GCT Ala AAC Asn AGC Ser ATC	Pro GAT ASD GGC Gly GGT Gly Ser TAC Tyr AAC Asn Ser CCC Pro CGA	Pro GGC GIV GTG Val TAC Tyr CCC Pro AAC Asn GGG GIY GCC	Pro AAG Lys GGC Gly GGC Ala TTC Phe ATT Ile Met TGG	Pro CCA Pro CTC Leu GGC Gly GGG Gly Ala GTG Val CCG Pro	TGC CVS AAT ASN GCG Ala CCT Pro AAC ASN CAG GIN	CCC Pro Ala GCC Ala TCC Ser Pro TTC Phe Pro AGC Ser Gly	GGG GIV TAC TYT TGC Cys CCA Pro Ala GGC GIY AAC AAC	GAC ASD GGT Gly AGC Ser GTC Val TCG Ser	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly	GCG Ala AAC Asn GCC Gly GCG Pro GAC Asp GTG GTG GTG	CCC Pro Ala GCC Ala TAC Tyr GCC Ala Pro TTG Leu TCC Ser	TAC Tyr TAC Tyr AGC Ser Thr Ala AAT Asn ACG Thr	GCG Ala CCC Pro Cys GCC Ala CCC Ala CC	CCT Pro GCC Ala ACT Thr GCC Ala Ser GTT Val CAT His	GCC Ala TAT Tyr GCC Ala GCC Ala GCC Ala CAG Gln GGT Gly
849 225 897 241 945 257 993 273 1041 289 1089 305	Pro CGC Arg TAC Tyr CCG Pro GCT Ala AAC Asn AGC Ser ATC Ile	Pro GAT ASD GGC Gly GGT Gly Ser TAC Tyr AAC Asn Ser CCC Pro CGA Arg	Pro GGC GIV GTG Val TAC Tyr CCC Pro AAC Asn GGG Gly GCC Ala	Pro AAG Lvs GGC Gly GGC Gly TTC Phe ATT Ile Met TGG Trp	Pro CCA Pro CTC Leu GGC Gly Ala GTG Val CCG Pro TAG	TGC CVS AAT ASN GCG Ala CCT Pro AAC ASN CAG GIN GGAA	CCC Ala CCC ACC ACC ACC ACC ACC ACC ACC ACC AC	GGG GIV TAC TYT TGC Cys CCA Pro Ala GGC GIY AAC ASn ACCCCC	GAC ASD GGT Gly AGC Ser GCG Ala GTC Val TCG Ser	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly GGA Gly	GCG Ala AAC AAS AS GGC Gly CCG Pro AS GAC Asp CTG GAC GAC GAC GAC GAC GAC GAC GAC GAC GA	CCC Pro Ala GCC Ala TAC Tyr GCC Ala Pro TTG Leu TCC Ser	TAC Tyr TAC Tyr TAC Tyr AGC Ser ACT Thr Ala AAT Asn ACG Thr	GCG Ala CCC Pro Cys GCC Ala GCG Ala CTGC CTG CCG CTGC CTGC CTGC CTGC CTGC	CCT Pro GCC Ala Thr Thr GCC Ala Ser GTT Val CAT His	GCC Ala TAT Tyr GCC Ala GCC Ala GCC Ala CAG Gln GGT Gly
849 225 897 241 945 257 993 273 1041 289 1089 305	Pro CGC Arg TAC Tyr CCG Pro AAC Asn AGC Ser ATC Ile ATC TTC TTC TTC	Pro GAT ASD GGC Gly GGT Gly TAC GTY TAC ASD CCC CGA Arg CCC CCC CCC CCC CCC CCC CCC CCC CCC C	Pro GGC Gly GTG Val TAC Tyr CCC Pro AAC Asn GGG Gly GCC Asn GCC Tyr	AAG LVS GGC Gly GGC Ala TTC Phe ATT Ile Met TGG TTP TGG TTP TGG TTP TGG TTP TGG TGG	Pro CCA Pro CTC Leu GGC Gly Ala GTG Val CCG Pro TAG TTGCCCCTF	TGC CVS AAT ASn GCG Ala CCT Pro AAC ASn GAG GGAA GGAGA GGAGA	CCC Pro Ala CCC Ala TCC Ser Pro TTC Phe Pro AGC Ser Gly GGGA	GGG GIV TAC TYT TGC Cys CCA Pro Ala GGC GIY AAC ASS ACCCCC	GAC ASD GGT Gly AGC Ser GCG Ala TCG Ser CCGTC	TCG Ser Pro TAT Tyr CCT Pro CAG Gln CAG Gly CGCACGCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC	GCG Ala AAC Asn GCG Gly CCG Pro GAC Asp GTG GTG GTG GTG GTG GTG GTG GTG GTG GT	CCC Pro Ala GCC Ala TAC Tyr GCC Ala Pro TTG Leu TCC Ser CCTGA	TAC Tyr TAC Tyr AGC Ser Thr Ala AAT Asn CCGA	GCG Ala CCC Pro Cys GCC Ala CTGC Ala CTGC CTGC CTGC CTGC CTGC CTGCC CTGCC CTGCC	CCT Pro GCC Ala ACT Thr GCC Ala Ser GTT Val CAT His CACCT	GCC Ala TAT Tyr GCC Ala GCC Ala GCC Ala GCG Ala CAG GIn CAG GIy CCAAC
849 225 897 241 945 257 993 273 1041 289 1089 305 1137 321	Pro CGG Arg TAC Tyr CCG Pro GCT Ala AAC ASn ATC Ile ATC TAGTI	Pro GAT ASD GGC Gly Ser TAC TYr AAC Asn Ser CCC CGA Arg CCCT CTTOTO	Pro GGC Glv GTG Val TAC Tyr CCC Pro AAC AASn GGG Gly GCC Ala GCC AIa	AAG Lys GGC Gly GGC Ala TTC Phe TTC TTG TTG TTG TTG TTG TTG TTG TTG TTG	Pro CCA Pro CTC Leu GGC Gly Ala GTG Val TAG TAG	TGC CVS AAT ASI GCG Ala CCT Pro AAC CAG GIII GGAAA CGAGAAA CCAGGAAA	CCC Pro Ala GCC Ala TCC Ser Pro TTC Phe Pro AGC Ser Gly AGCGA	GGG GIV TAC TYF TGC Cys CCA APA AAC ASn ACCCCC	GAC ASD GGT Gly AGC Ser AGC Ser TCG GTC CCCAA	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly GCGCCC	GCG Ala AAC Asn CCG Gly CCG Pro GAC Asp GTG Val GACCGGACCGTGGG	CCC Pro Ala GCC Ala TAC Tyr GCC Ala Pro TTG Leu TCC Ser CCTG#	TAC Tyr TAC Tyr TAC Tyr AGC Ser Thr Ala AAT Asn CCGF	GCG Ala CCC Pro TGC Cys GCC Ala GCG Ala Thr CTG CLG CTGCC CTGCC	CCT Pro GCC Ala ACT Thr GCC Ala Ser GTT Val CATTLIS CACCT	GCC Ala TAT Tyr GCC Ala GCC Ala GCC Ala GCC Ala GCC Ala GCC Ala GCC ACG GIN GCC ACG GIN GCC ACG GIN GCC ACG GIN GCC ACG ACG
849 225 897 241 945 257 993 273 1041 289 1089 305 1137 321	Pro CGC Arg TAC Tyr CCG Pro Ala AAC Asn ATC Ile AGCT TTCF AGCT CCCCC CCCC CCCC CCCC CCCC CCC CCC CC	Pro GAT Asp GGC Gly GGT TAC Tyr AAC Asn Ser CCC CGA Arg CCCA Arg CCCA CCCA CCCA CCCA CCCCA CCCCCA CCCCCA CCCCA CCCCA CCCCA CCCCA CCCCCA CCCCCC	Pro GGC Gly GTG Val TAC TYC Pro AAC Asn GGG Gly GCC Ala GCC Ala GCC Ala	Pro AAG Lvs GGC Gly GGC Ala TTC Phe ATT Ile TGG Trp CCTCG GGAGAA CCTC	Pro CCA Pro CTC Leu GGC Gly Ala GTG Val TAG TAG	TGC CVS AAT ASn GCG Ala CCT Pro CAG GGAA GGAA GGAA GGAA GGAA GGAA G	CCC Pro Ala GCC Ala TCC Ser Pro AGC Ser Gly GGGA	GGG GIV TAC TYP TGC Cys CCA Pro Ala GGC GIV AAC CCCC CTATATICACCCCC	GAC ASD GGT Gly AGC Ser GCG Ala AGC GTC Val TCG SCGTC CCCAA CCCCCCCCCCCCCCCCCCCCCCCCCCCCC	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGA GCGC CCATG CCA	GCG Ala AAC Asn GCG Gly CCG Pro GAC	CCC Pro Ala GCC Ala TAC Tyr GCC Ala Pro TTG Leu TCC Ser CTGA GCCT ALACTGACTGACTGACTGACTGACTGACTGACTGACTGACTG	TAC Tyr TAC Tyr TAC Tyr AGC Ser Thr AAT AAT ASI ACG TTCCC TTCC TTCCC TTCC TTC TTCC TTCC TTC T	GCG Ala CCC Pro TGC Cys GCC Ala CTG Ala CTG CTGC CTGC CTGC CTGCC TTCCC TTGCC TTGCC TTGCC	CCT Pro CCT Pro CCC Ala ACT Thr GCC Ala Ser GTT Val CATH SCACCT CATTINGCACCT CCATTINGCACCT CCATTINCCACCT CCATTINGCACCT CCATTINGCACCT CCATTINGCACCT CCATTINGCACCT C	GCC Ala TAT Tyr GCC Ala GCC Ala GCC Ala GCC Ala GCC Ala CAG Gln CAG GT GTy CCAAC
849 225 897 241 945 257 993 273 1041 289 1089 305 1137 321 1196 1260 1324 1388 1452	Pro CGC Arg TAC Tyr CCG Pro GCT Ala AAC Asn AGC Ser ATC Ile AGCT CCG AGT AGT CCCC	Pro GAT ASD GGC Gly Ser TAC Tyr AAC Ser CCC Pro CGA Arg CCCTTCTCC	Pro GGC GlV GTG Val TAC TYr CCC Asn GGG Gly GCC Ala GGC GITGC GCC GCTGG	Pro AAG Lys GGC Gly GCC Ala ATT Ile Met TGG Trp ATT CGGAGAGAGAGAGAGATCCCATC	Pro CCA Pro CTC CTC Leu GGC Gly GGG Gly Ala TAG CCG Pro TAG TAG	TGC CVS AAT ASn GCG Ala CCT Pro AAC ASn CAG GIn GGAGAGAGAGAGAGAGC GGAGAGAGC GGAGAGC GGCC GGCC GGCC GGCC CCGCC CCCC CCCC CCCC CCCC CCCC CCCC CCCC CCCC	CCC Pro Ala GCC Ala CFP Pro AGC Ser Gly GGGG AGGC CTTT GCC CTTT GCC CTTT GCC CCATC GCCATC GCC	GGG GIV TAC TYF TGC Cys CCA Ala GGC GIY AAC Asn ACCCCC GGCTCTTTCT CAATC	GAC ASD GGT Gly AGC Ser AGC Ser TCG GCG ALI A TCG Ser CCCAA CCCAA CCCCAC CCCAA CCCCAA CCCCCAA CCCCAA CCCCCAA CCCCCC	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly GGAATG	GCG Ala AAC Asn GCG Gly GCG GSCG GAC GACC GACC GACC GACC GACC GACC G	CCC Pro Ala GCC Ala TAC Tyr TCC Ser TCC Ser TCC Ser CCTGA	TAC Tyr TAC Tyr TAC Tyr AGC Ser ACT Thr Ala AAT AAT ACG Thr CCGF	GCG Ala CCC Pro TGC Cys GCC Ala Thr CTG Ala Thr CTG Leu TCCC	CCT Pro GCC Ala ACT Thr GCC Ala CAC Ala CAC Ala GCC Ala GCC Ala GCC Ala GCC CAT His CACCI GCAC GCACCI GCAC	GCC Ala TAT Tyr GCC Ala GCC Ala GCC Ala CAG Gln CAG Gly CAAC
849 225 897 241 945 257 993 273 1041 289 1089 305 1137 321 1196 1260 1260 1324 1388	Pro CGC Arg TAC Tyr CCG Pro GCT Ala AAC Asn AGC Ser ATC Ile AGCT CCG AGT AGT CCCC	Pro GAT ASD GGC Gly Ser TAC Tyr AAC Ser CCC Pro CGA Arg CCCTTCTCC	Pro GGC GlV GTG Val TAC TYr CCC Asn GGG Gly GCC Ala GGC GITGC GCC GCTGG	Pro AAG Lys GGC Gly GCC Ala ATT Ile Met TGG Trp ATT CGGAGAGAGAGAGAGATCCCATC	Pro CCA Pro CTC CTC Leu GGC Gly GGG Gly Ala TAG CCG Pro TAG TAG	TGC CVS AAT ASn GCG Ala CCT Pro AAC ASn CAG GIn GGAGAGAGAGAGAGAGC GGAGAGAGC GGAGAGC GGCC GGCC GGCC GGCC CCGCC CCCC CCCC CCCC CCCC CCCC CCCC CCCC CCCC	CCC Pro Ala GCC Ala CFP Pro AGC Ser Gly GGGG AGGC CTTT GCC CTTT GCC CTTT GCC CCATC GCCATC GCC	GGG GIV TAC TYF TGC Cys CCA Ala GGC GIY AAC Asn ACCCCC GGCTCTTTCT CAATC	GAC ASD GGT Gly AGC Ser AGC Ser TCG GCG ALI A TCG Ser CCCAA CCCAA CCCCAC CCCAA CCCCAA CCCCCAA CCCCAA CCCCCAA CCCCCC	TCG Ser Pro TAT Tyr CCT Pro CAG Gln GGG Gly GGAATG	GCG Ala AAC Asn GCG Gly GCG GSCG GAC GACC GACC GACC GACC GACC GACC G	CCC Pro Ala GCC Ala TAC Tyr TCC Ser TCC Ser TCC Ser CCTGA	TAC Tyr TAC Tyr TAC Tyr AGC Ser ACT Thr Ala AAT AAT ACG Thr CCGF	GCG Ala CCC Pro TGC Cys GCC Ala Thr CTG Ala Thr CTG Leu TCCC	CCT Pro GCC Ala ACT Thr GCC Ala CAC Ala CAC Ala GCC Ala GCC Ala GCC Ala GCC CAT His CACCI GCAC GCACCI GCAC	GCC Ala TAT Tyr GCC Ala GCC Ala GCC Ala GCC Ala GCC Ala CAG Gln CAG GT GTy CCAAC

1388 CCCAGGAGTGCCCTCCGAGGTCCATGGGCACCCCCGTTTGGAACTGGACTGAGCTGGACTGACCTCGGC 1452 CGCAGGGCCTGAGATCTGGCGGCCCATTCCGCGAGCCAGGCCGGGGCCCGGGCCCTTTGCTL 1516 CTCGCCGTCGCCCCCCCCCCCCCCCCCCCTATTTATGTTTTTACCTATTGCTGTAAGAAATC 1580 CGATCC

FIG. 1. Nucleotide and predicted amino acid sequence of hCsx

The top and middle lines indicate nucleotide and amino acid sequence of *hCsx*, respectively. The bottom line indicates identical amino acid sequence with mouse *Csx/Nkx2.5* by dots, dashes indicate gaps between the human and mouse sequences, and non-identical amino acids are noted by their three letter code. The homeodomain is boxed. The conserved amino terminus TN-domain and the NK2-box located in the carboxy terminus following the homeobox are underlined. While out-of-frame start codons are found upstream of the predicted initiation codon, no in-frame stop codons are present. This sequence has been deposited to GenBank database (Accession no. U34962).




FIG. 2. hCsx sequence comparison and schematic diagram

(A) Interspecies sequence comparison of the *hCsx* conserved domains. a, Homeodomain; b, TN-domain; c, NK2 domain. Dashes indicate amino acid identity with *hCsx*. The three helix motifs of the homeodomain are overlined. There is 100% identity between the murine *Csx* homeodomain and the *hCsx* homeodomain. In addition, the NK-2 and TN domains are completely conserved between the human, mouse, and *Xenopus* genes. (B) Schematic diagram of the *hCsx* cDNA. Entire boxed area indicates the coding region; thick lines, untranslated regions. The three *hCsx* subdomains are indicated in the figure. The probes used in the hybridizations and ribonuclease protection assays as well as the location of PCR primers are shown in the diagram (see text for details).

TN-domain and the NK2 box, the identity is 100% among the human, mouse, and *Xenopus* genes (Fig. 2A, b and c). The *hCsx* homeodomain shows very low homology (less than 50%) to most known homeodomains with the exception of those in the NK2 gene family of *Drosophila*, *Xenopus*, and mouse.

Expression of hCsx in Human Tissues

To examine the tissue distribution of *hCsx* transcripts, a Northern blot containing poly A⁺ RNA from several adult human tissues was examined. A band corresponding to a transcript size of approximately 1.6 kb was detected exclusively in




FIG. 3. Northern blot analysis of hCsx mRNA

The upper panel shows a human multiple tissue northern blot containing 2 μ g of poly A⁺ RNA from eight different adult tissues probed with a 5' portion of the hCsx cDNA (nucleotides 1–608, Probe C, Fig. 2B). Hybridization signals were seen only in the heart lane. Hybridization of the blot with a PstI fragment containing the entire coding region and a part of the 3' untranslated region of the rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is shown in the lower panel to verify RNA integrity (23). Unequal loading of the lanes is noted with more intense bands in the placenta and pancreas lanes.

the heart (Fig. 3). There was another lighter band in the heart lane of approximately 3 kb as well. It may correspond to unprocessed RNA of the same transcript or the product of a related gene. No signal was detected in the other adult tissues examined including brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas.

To examine the level of expression of hCsx in human fetal heart and in different pathologic states, RNase protection analysis was performed using a probe corresponding to the 3' end of hCsx cDNA (Fig. 2B, Probe D). A human γ -actin probe

corresponding to the 3' untranslated region was used as an internal control (Fig. 4A). Densitometric analysis of hCsx transcript normalized by y-actin message is shown in Fig. 4B. The hCsx transcript was detected at 12 weeks of embryonic development, the earliest time point examined. There was 5-fold increase in the hCsx message occurring between 12 and 19 weeks (Fig. 4B). To determine whether expression of hCsx mRNA is altered in the failing human myocardium, we analyzed left ventricular RNA samples from patients with ischemic cardiomyopathy (n = 6) and idiopathic dilated cardiomyopathy (n = 6) and two patients with congenital heart disease. No significant difference in abundance of hCsx message in the different pathologic states was detected. (Fig. 4 A and B).

Isolation of Genomic Clone of hCsx

In order to begin to characterize the genomic organization of hCsx gene, a human genomic Pl clone containing the hCsx gene was isolated by PCR as described in Materials and Methods. PCR analysis of the P1 genomic clone confirmed that it contained sequences of the cDNA from the 5' untranslated and coding region using primer pair P2S/P2AS (Fig. 2B), and the homeodomain region using primer pair P3S/P3AS (Fig. 2B). The primers used were, P2S: 5'-CGTGGGCAGCG CCGCTTT-3', P2AS: 5'-GTCGGGGTCGCTGTA GGCAC G-3', P3S: 5'-CCCCGGGCGCGACGGCG GAGG-3', P3AS: 5'-CAGAGTCTGGTCCTGCCG CTG-3'. An intronic sequence upstream of the homeobox was also amplified using primer pair P4S/P4AS (Fig. 2B). PCR reactions using primer pair P4S/P4AS with the hCsx cDNA template gave an expected size band (288 bp), while an approximately 1.8-kb product was detected when the hCsx P1 genomic clone was used as a template (data not shown).

Hybridization of a human genomic Southern blot with Probe A (containing the 5' end of the cDNA, Probe A, Fig. 2B) and subsequently with Probe B (containing the homeobox and the NK2 box, Probe B, Fig. 2B), detected a predominant band in each lane as well as other faint bands (data not shown). These results suggest that this gene is present in a single locus in the human genome, but that there are likely other related genes (perhaps containing an *hCsx*-like homeodomain and NK2 box) that remain to be isolated in the human genome.




FIG. 4. Expression of hCsx mRNA in human fetal heart and different pathologic states

(A) Representative composite autoradiogram showing expression of hCsx mRNA in human myocardium from selected fetal stages and several pathologic states. Total RNA (5 μ g) was used for each lane and ribonuclease protection analysis was performed using hCsx and gamma-actin antisense riboprobes. Yeast tRNA (10 μ g) was used as a negative control. The left panel shows the undigested probes, hCsx, 523 nucleotides (nt) in length and γ -actin, 145 nt in length. Protected fragments of the expected sizes (hCsx, 428 nt; γ -actin, 140 nt) were present in all samples examined. (B) Densitometric analysis of hCsx transcript levels during human embryonic development and in different disease states of the LV myocardium. The relative abundance of the hCsx mRNA was normalized to the level of γ -actin mRNA in each sample. Densitometric score of the normal control was defined as 1.0. Data shown represents the mean ± SEM. LV, left ventricle; WK, week; NRML, normal; DCM, dilated cardiomyopathy (n =6); ICM, ischemic cardiomyopathy (n = 6); CHD, congenital heart disease (n = 2).




FIG. 5. Polymerase chain reaction (PCR) assay with Human/Rodent Somatic Cell Hybrid Panel #2

PCR products were run on 2% agarose gel stained with ethidium bromide. The expected size band appeared only with human chromosome 5, indicated by the arrow. Controls for the mapping panel appear in the lower three right lanes. An identically sized band to that with chromosome 5 appears in the Lane H, representing human cell line IMR91 DNA (positive control). M, DNA from mouse line 3T6, C, represents Chinese hamster line RJK88 DNA. The lane labeled $\rm H_2O$ is a negative control lane with water in place of template in the reaction mix.

Chromosomal Location of hCsx Gene

The mouse *Csx/Nkx2.5* gene maps within the *t*-locus of the mouse chromosome 17 (Ref. 31 and Issei Komuro, Neal Copeland, D.T., and S.I., unpublished data). This region of mouse chromosome 17 has been shown to have synteny homology to human chromosome 6 (32). To determine chromosomal location of the *hCsx* gene, somatic cell hybrid PCR analysis was performed using the Human/Rodent Somatic Cell Hybrid Panel #2. A band of the expected size (229 bp) was reproducibly detected in human chromosome 5 (Fig. 5). This PCR product was subcloned and sequenced, which showed 100% homology with the *hCsx* cDNA sequence.

In order to determine the chromosomal location of *hCsx* more specifically, FISH analysis was performed using the entire P1 clone as a probe. A pair of signals from both chromatids was present in the long arm of a B-group chromosome. After banding, the signal was localized in the distal portion of chromosome 5 on band q35, close to the junction with band 5q34 (Fig. 6 A–C). No signal was detected by FISH on chromosome 6, confirming the results of somatic cell hybrid PCR analysis.




FIG. 6. Chromosomal localization of the hCsx gene

(A) Idiogram of human chromosome 5 showing hCsx localization. A vertical line shows the region where the hCsx gene is located, 5q34-q35. (B) Fluorescent in situ hybridization analysis of a metaphase diploid cell demonstrates a pair of signals (white arrows) in the distal portion of the long arm of a B-group chromosome. (C) Partial G-banding karyotype of the same slide shows that the signals (black arrows) correspond to the 5q34-35 region.

DISCUSSION

Homeobox genes play critical roles in tissue organization by regulating downstream target genes (8). As with the widely studied *Hox* genes, the NK family seems to be evolutionarily conserved and duplicates may have arisen from a single gene (6). In this report we describe the first human gene isolated to date that belongs to the NK family of homeobox genes. The homeodomain regions of the NK family members are more closely related to each other than to other homeodomains (9). While the functional significance of the additional conserved domains, the NK-2 domain and the TN domain, are not known, these domains represents another area of close relationship among these genes in several species. In adult human tissues, hCsx expression appears to be restricted to the heart. This tissue restricted pattern of expression is evolutionarily conserved among diverse species including Drosophila (15), Xenopus (30), mouse (17,18), and humans.

In mammals, cardiac muscle cells are derived from the anterior lateral plate mesoderm. In humans, commitment of mesodermal cells to the cardiac lineage occurs very early, when cells migrate to form the cardiogenic area at the beginning of the third week of human embryonic development (33). By the end of the 3rd week the primitive heart is formed and soon becomes functional, perfusing the different embryonic tissues and allowing normal development of the human embryo (33). We detected the hCsx transcript at 12 weeks, the earliest time point available. Since in the mouse, Csx/Nkx2.5 transcript is present as early as 7.5 days p.c. (17,18), it is likely that hCsx transcript may have been present much earlier, perhaps as early as at the time of commitment of the cardiogenic area (around 16 to 18 days of human development) (33,34). There was a significant increase in hCsx transcript level between 17 and 19 weeks gestational age (Fig. 4B). At this time there is rapid growth of the heart and an associated increase in the ventricular stroke volume (35-37). In the mouse, Csx/ Nkx2.5 expression is relatively constant from late embryonic to adult stages (17). Similarly, levels of expression of hCsx appear relatively stable from the mid-embryonic stage to the adult; however, a more detailed study is necessary to make this a final conclusion.

Because *Drosophila tinman* and mouse *Csx/Nkx2.5* are essential for heart development, we hypothesized that expression of *hCsx* may be altered in disease states. However, there was no significant change in the level of expression of the *hCsx* transcript in human idiopathic dilated and ischemic cardiomyopathy as well as the two

congenital heart disease samples examined. It should be noted that these samples are from the end stage of heart failure and we can not rule out the possibility that levels of expression of hCsx may be altered in the earlier stages of the disease processes. Furthermore, our results neither rule out the possibility of an altered expression of the hCsx protein nor possible existence of point mutations in the hCsx gene in other forms of congenital cardiopathies (38).

By FISH, hCsx maps to the 5q34-q35 region. Synteny homology of mouse chromosome 17, where the Csx/Nkx2.5 gene maps, suggested that the human homolog would likely reside on chromosome 6 (Fig. 7). The localization of hCsx to the distal portion of chromosome 5q is unexpected since adjacent human genes surrounding the mouse Csx/Nkx2.5 locus have been assigned to human chromosome 6. However, no synteny has been studied in the specific region where the mouse Csx/Nkx2.5 gene is located, the th20 region (31). The unambiguous assignment of hCsxto human chromosome 5q (Figs. 5 and 6 A-C), suggests the introduction of a novel synteny group between human chromosome 5q and mouse chromosome 17. There is another gene, Fer, located on human chromosome 5, which is also present on mouse chromosome 17, outside of the t-locus (Figure 7) (32). Alternatively, this disrupted region of homology may be due to a chromosomal rearrangement.

In the genetic cascade for heart morphogenesis, a number of genes are activated sequentially to produce proteins which are necessary for normal development. When any of these genes are altered, a phenotypic abnormality of the heart may occur, depending on where the gene is located in this epigenetic cascade (39-41). A strictly anatomical classification of congenital heart disease is evolving into a newer classification schema according to the affected developmental stage of cardiac morphogenesis (42). In general, duplications of any given chromosome portion produce a less severe phenotype than deletions (43). In the case of chromosome 5q, there are at least 25 cases reported in the literature with distal 5q trisomies. The predominant phenotype includes growth and mental retardation as well as facial abnormalities and a high incidence (at least 67%) of congenital heart disease. Among the cardiac malformations, ventricular septal defect is the most common in these patients (44). To date, no homozygous deletions have been reported in the distal portion of the chromosome 5q (43). This raises the possibility of




FIG. 7. Approximate composite map of mouse genes surrounding the *Csx/Nkx2.5* locus

On the left is the human chromosomal localization of the corresponding mouse genes showing the regions of mouse-human synteny homology (see text for details). *Mutated regions in which individual genes have not been cloned to date (31,32). The dark box indicates the th20 locus (see text for details).

an extremely critical role of this segment during human embryogenesis, with its loss resulting in fetal demise during the early embryonic period (45,46). In fact, a lethal spontaneous deletion of the th20 locus has been reported in the mouse; however, whether the lethality of this deletion is directly related to the loss of *Csx/Nkx2.5* or to other closely linked genes is not known (47).

In summary, we have isolated the first human member of the NK family of homeobox genes. This gene, hCsx, appears to be the homolog of murine Csx/Nkx2.5 and Drosophila tinman. Since null mutations of Csx/Nkx2.5 and tinman genes cause a severe early cardiac defect, it is possible that mutations in hCsx may be discovered in some forms of congenital heart disease. Future studies will test this hypothesis.

ACKNOWLEDGMENTS

We thank Ann Burgess, Madhu Prasad, and Mary Richmond for excellent technical assistance; T. Takahashi and P. D. Allen for RNA samples; and N. G. Copeland, T. W. Glover, S. A. Camper, and D. Law for helpful comments on

the manuscript. This work was supported in part by grants from the National Institutes of Health and the American Heart Association to SI.

REFERENCES

- 1. Weintraub H, Davis R, Tapscott S, et al. (1991) The myoD gene family: Nodal point during specification of the muscle cell lineage. *Science* **251:** 761–766.
- 2. Olson E, Klein WH. (1994) bHLH factors in muscle development: Deadlines and commitment, what to leave in and what to leave out. *Gene Dev.* 8: 1–8.
- 3. Rudnicki MA, Schnegelsberg PNJ, Stead RH, Braun T, Arnold HH, Jaenisch R. (1993) MyoD or Myf-5 is required for the formation of skeletal muscle. *Cell* **75**: 1351–1359.
- 4. Gehring WJ. (1994) A history of the homeobox. In: Duboule D (ed). *Guidebook to the Homeobox Genes*. Oxford University Press, Oxford, pp. 3–10.
- 5. Gehring WJ, Qian YQ, Billeter M, et al. (1994) Homeodomain-DNA recognition. *Cell* **78:** 211–223.
- 6. Burglin TR. (1994) A Comprehensive classification of the homeobox genes. In: Duboule D (ed). Guidebook to the homeobox genes. Oxford University Press, Oxford, pp. 27–71.
- 7. Beeman RW. (1987) A homeotic gene cluster in the red flour beetle. *Science* **327**: 247–249.
- 8. Gehring WJ, Affolter M, Burglin T. (1994) Homeodomain proteins. *Annu. Rev. Biochem.* **63:** 487–526.
- 9. Kim Y, Nirenberg M. (1989) Drosophila NK-homeobox genes. *Proc. Natl. Acad. Sci. U.S.A.* **86:** 7716–7720.
- 10. Dohrmann C, Azpiazu N, Frasch M. (1990) A new *Drosophila* homeobox gene is expressed in mesodermal precursor cells of distinct muscles during embryogenesis. *Gene Dev.* **4:** 2098–2111.
- 11. Duboule D. (1994) Description of the homeobox genes. In: Duboule D (ed). *Guidebook to the Homeobox Genes*. Oxford University Press, Oxford, pp. 75–246.
- 12. Price M, Lazzaro D, Pohl T, et al. (1992) Regional expression of the homeobox gene Nkx2.2 in the developing mammalian forebrain. *Neuron* 8: 241–255.
- 13. Azpiazu N, Frasch M. (1993) Tinman and bagpipe: Two homeobox genes that determine cell fates in the dorsal mesoderm of *Drosophila. Gene Dev.* **7:** 1325–1340.

- 14. Bodmer R, Jan LY, Jan YN. (1990) A new homeobox-containing gene, *msh-2*, is transiently expressed early during mesoderm formation of *Drosophila*. *Development* **110**: 661–669.
- 15. Bodmer R. (1993) The gene *tinman* is required for specification of the heart and visceral muscles in *Drosophila*. *Development* **118**: 719–729.
- 16. Bodmer R. (1995) Heart development in *Drosophila* and its relation to vertebrates. *Trends Cardiovasc. Med.* **5:** 21–28.
- 17. Komuro I, Izumo S. (1993) *Csx*: A murine homeobox-containing gene specifically expressed in the developing heart. *Proc. Natl. Acad. Sci. U.S.A.* **90:** 8145–8149.
- 18. Lints TJ, Parsons LM, Hartley L, Lyons I, Harvey RP. (1993) *Nkx-2.5*: A novel murine homeobox gene expressed in early heart progenitor cells and their myogenic descendants. *Development* **119**: 419–431.
- 19. Lions I, Parsons LM, Hartley L, Harvey RP. (1995) Myogenic and morphogenetic defects in the heart tubes of murine embryos lacking the homeobox gene *Nkx2.5*. *Gene Dev.* **9**: 1654–1666.
- Heikinheimo M, Scandrett JM, Wilson DB. (1994) Localization of transcription factor GATA-4 to regions of the mouse embryo involved in cardiac development. *Devel. Biol.* 164: 361–373.
- Edmondson DG, Lyons GE, Martin JF, Olson EN. (1994) *Mef2* gene expression marks the cardiac and skeletal muscle lineages during mouse embryogemesis. *Development* 120: 1251–1263.
- 22. Tamkun MM, Knoth KM, Walbridge JA, Kroemer H, Roden DM, Glover DM. (1991) Molecular cloning and characterization of two voltage-gated K channel cDNA from human ventricle. *FASEB J* 5: 331–337.
- 23. Takahashi T, Allen PD, Izumo S. (1992) Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. *Circ. Res.* **71:** 9–17.
- 24. Sambrook J, Fritsch EF, Maniatis T. (1989)

 Molecular Cloning: A Laboratory Manual. 2nd
 Ed. Cold Spring Harbor Laboratory Press,
 Cold Spring Harbor, NY.
- 25. Church GM, Gilbert W. (1984) Genomic sequencing. *Proc. Natl. Acad. Sci. U.S.A.* **81:** 1991–1995.
- 26. Shepherd NS, Pfrogner BD, Coulby JN, et al. (1994) Preparation and screening of an arrayed human genomic library generated

- with the P1 cloning system. *Proc. Natl. Acad. Sci. U.S.A.* **91:** 2629–2633.
- 27. Pierce JC, Sauer B, Stenberg N. (1992) A positive selection vector for cloning high molecular weight DNA by the bacteriophage P1 system: Improved cloning efficacy. *Proc. Natl. Acad. Sci. U.S.A.* **89:** 2056–2060.
- 28. Wechsler DS, Hawkins AL, Li X, Wang Jabs E, Griffin CA, Dang CV. (1994) Localization of the human Mxi1 transcription factor gene (MXII) to chromosome 10q24-q25. Genomics 21: 669-672.
- 29. Kozak M. (1987) An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. *Nucleic Acid. Res.* **15:** 8125–8132.
- 30. Tonissen KF, Drysdale TA, Lints TJ, Harvey RP, Krieg PA. (1994) *XNkx-2.5*, a *Xenopus* gene related to *Nkx-2.5* and *tinman*: Evidence for a conserved role in cardiac development. *Devel. Biol.* **162**: 325–328.
- 31. Himmelbauer H, Harvey RP, Copeland NG, Jenkins NA, Silver LM. (1994) High-resolution genetic analysis of a deletion on mouse chromosome 17 extending over the fused, tufted, and homeobox *Nkx2.5* loci. *Mamm. Genome* **5:** 814–816.
- 32. Forejt J, Artzt K, Barlow D, et al. (1994) Mouse chromosome 17. *Mamm. Genome* **5(Suppl):** S238–S258.
- 33. Moorman AFM, Lamers WH. (1994) Molecular anatomy of the developing heart. *Trends Cardiovasc. Med.* **4:** 257–264.
- 34. Litvin J, Montgomery M, Gonzalez-Sanchez A, Bisaha JG, Bader D. (1992) Commitment and differentiation of cardiac myocytes. *Trends Cardiovasc. Med.* **2:** 27–32.
- 35. John Sutton MG, Raichlen JS, Reichek N, Huff DS. (1984) Quantitative assessment of right and left ventricular growth in the human fetal heart: A pathoanatomic study. *Circulation* **70:** 935–941.
- 36. John Sutton MG, Gewitz MH, Shah B, et al. (1984) Quantitative assessment of growth and function of the cardiac chambers in the normal fetus: A prospective longitudinal echocardiographic study. *Circulation* **69:** 645–654.
- 37. Kenny JF, Plappert T, Doubilet P, et al.

- (1986) Changes in intracardiac blood flow velocities and right and left ventricular stroke volumes with gestational age in the normal human fetus: A prospective Doppler echocardiographic study. *Circulation* **74**: 1208–1216.
- 38. Dietz HCI, Pyeritz RE. (1994) Molecular genetic approaches to the study of human cardiovascular disease. *Annu. Rev. Physiol.* **56**: 763–796.
- 39. Nora JJ. (1993) Causes of congenital heart diseases: Old and new modes, mechanisms, and models. *Am. Heart J.* **125:** 1409–1419.
- 40. Bouvagnet P, Sauer U, Debrus S, et al. (1994) Deciphering the molecular genetics of congenital heart disease. *Herz* **19:** 119–125.
- 41. Zavala C, Jimenez D, Rubio R, Castillo-Sosa ML, Diaz-Arauzo A, Salamanca F. (1992) Isolated congenital heart defects in first degree relatives of 185 affected children. Prospective study in mexico city. *Arch. Med. Res.* 23: 177–182.
- 42. Perry LW, Neill CA, Ferencz C, Rubin JD, Loffredo CA. (1994) Infants with congenital heart disease: the cases. In: Ferencz C, Rubin JD, Loffredo CA, Magee CA (eds). Perspectives in Pediatric Cardiology, Epidemiology of Congenital Heart disease. Futura Publishing Company, Mount Kisco, NY. Vol. 4, pp. 33–62.
- 43. Borgaonkar DS. (1991) Chromosomal Variation in Man: A Catalog of Chromosomal Variants and Anomalies. 6th Ed. Wiley-Liss, New York.
- 44. McDonald M, Maynard S, Sheldon S, Innis J. (1994) Unbalanced 5;16 translocation in a boy with papillary Thyroid carcinoma. *Am. J. Med. Genet.* **49:** 288–293.
- 45. Fryns JP, Kleczkowska A, Kubien E, Petit P, Van den Berghe H. (1984) Cytogenetic survey in couples with recurrent fetal wastage. *Hum. Genet.* **65:** 336–354.
- 46. Byrne J, Warburton D, Kline J, Blanc W, Stein Z. (1985) Morphology of early fetal deaths and their chromosomal characteristics. *Teratology* **32:** 297–315.
- 47. Lyon MF, Bechtol K. (1977) Derivation of mutant t-haplotypes of the mouse by presumed duplication or deletion. *Genet. Res.* **30:** 63–76.